A peptide substitution in HIV-1 gp120 first hypervariable domain enhances its immunogenicity in mice

Area of Science:

• Immunology
• Virology
• Vaccine Development

Background:

• The human immunodeficiency virus type 1 (HIV-1) envelope (Env) protein is a key target for vaccine development.
• Incorporating conserved epitopes from other viral proteins into Env could enhance vaccine efficacy.

Purpose of the Study:

• To investigate the immunogenicity of HIV-1 gp120 modified with heterologous T cell epitopes.
• To assess if substitutions in hypervariable regions of gp120 affect its structural integrity and immune response.

Main Methods:

• In vitro mutagenesis was used to create HIV-1(LAI) Env gp120 variants.
• A 12-amino acid hemagglutinin (HA) peptide was substituted into the V1 or V3 hypervariable regions.
• Proteins were produced using recombinant vaccinia viruses and analyzed for structural properties and immunogenicity in mice.

Main Results:

• Substituted gp120 proteins retained structural integrity, including serological recognition and CD4 binding.
• gp120 substituted in the V1 domain elicited a significantly stronger serological immune response in mice compared to native or V3-substituted gp120.
• These findings suggest that gp120 can tolerate substantial modifications without compromising structure.

Conclusions:

• HIV-1 gp120 can accommodate large epitope substitutions, particularly in the V1 region.
• Such modifications may enhance the immunogenicity of Env-based vaccine candidates.
• This strategy holds promise for developing more effective HIV vaccines by incorporating conserved T cell epitopes.